

# The Elemental Diet

## INTRODUCTION

Elemental diets (EDs) have been around for over 50 years, yet few recognize what they are and their importance in clinical practice.<sup>1</sup> A review of the scientific literature reveals robust data validating the use of EDs for the dietary management of patients with limited or impaired capacity to digest, absorb, and/or metabolize foods.<sup>1</sup> The conditions referenced in the literature on EDs were initially confined to inflammatory bowel disease (IBD), Crohn's disease (CD),<sup>2,3</sup> and inflammatory ulcerative colitis (UC).<sup>4-7</sup> However, evidence is now suggesting that EDs can also help with small intestinal bacterial overgrowth (SIBO),<sup>8,9</sup> irritable bowel syndrome (IBS),<sup>10</sup> and other conditions that manifest outside the gastrointestinal system.<sup>11-22</sup>

A study published in the *Journal of Paediatric Gastroenterology and Nutrition* showed that an ED is as effective as corticosteroids in treating children with acute CD. In fact, the researchers concluded that the ED is a preferred therapy for these children as there are none of the side effects associated with steroid use.<sup>3</sup> Interestingly, even with the data and supportive literature, very few clinicians have used EDs for such conditions. One possible reason was the palatability of EDs, which led to poor compliance. However, EDs are now available that address this issue to drive patient compliance.

## WHAT IS AN ELEMENTAL DIET?

As the name suggests, an elemental diet is a "basic" medical food that contains all the daily recommended allowances for essential fatty acids, vitamins, minerals, and other nutrients required by the body for proper physiological functioning. An ED can be described as similar to a meal replacement for the day, however there is one major distinguishing characteristic: it has no whole proteins. Instead, it features pure, free-form amino acids. This allows the ED to be absorbed into the bloodstream within the first 2 ft, or proximal part, of the small intestine – an almost immediate assimilation.

This immediate absorption is possible because the ED consists of individual essential dietary compounds in their simplest forms, rendering the bulk of digestion unnecessary. The outcome is that it prevents food particles from reacting with the majority of the gastrointestinal tract, thus reducing many of the symptoms associated with various gastrointestinal conditions. But this is not the only advantage of the ED. Several other key effects result from an easy absorption of and lowered reactivity to food, which are detailed in the following sections.<sup>23</sup>

## MECHANISMS OF ACTION

EDs have numerous applications, with continued research on their effectiveness. The trials on EDs are impressive, however the work and clinical experience of health care professionals are also confirming and expanding these very applications.


While we still do not fully understand how EDs work, there are a number of proposed mechanisms of actions with supportive scientific literature, which are outlined below.

### 1. Improves nutritional status

Elemental diets have been shown to support the uptake of essential nutrients, correct negative nitrogen balance, improve nutritional status, and restore gut mucosal integrity in patients with IBD. It is thought that EDs may also improve omega-3 to omega-6 ratios, promote iron storage, improve bone remodeling, and increase muscle mass of patients with IBD.<sup>24</sup>

### 2. Reduces the production of gastric acid, pancreatic enzymes, and bile, all leading to a reduction in epithelial cell loss

Elemental formulas slow down the emptying of the stomach, but concomitantly reduce acid secretion and the release of pancreatic enzymes. This is because the volume of ingested food by itself activates mechanoreceptor responses, which in turn activate neuronal negative feedback loops. A lower volume will activate a signal to decrease the acid secretion. When the formula is sipped or infused at a slow rate, the mechanoreceptor responses may be decreased. Enteral nutrition provides obvious caloric nutritional support and is trophic (either directly or through neuronal loops) for the intestinal epithelial compartment, an effect likely to be beneficial, especially for ulcerative colitis (UC).<sup>1,24-26</sup>



### 3. Decreases free radicals

EDs decrease free radicals by increasing nutritional and therefore antioxidant status.<sup>27</sup>

### 4. Gives the gastrointestinal tract (small intestine) a rest

EDs are thought to rest the gastrointestinal tract by reducing the workload of digestion and absorption, and in peristalsis, allowing the promotion of epithelial healing.<sup>24-26</sup>

### 5. Decreases antigenicity

The decrease of total fat and elimination of whole proteins may lower the antigenicity in the intestinal lumen, thereby reducing inflammation in the gastrointestinal tract. Improved nutritional intake and status may also limit luminal antigen exposure and allow the improvement of barrier function.<sup>24</sup>

### 6. Improves the microbiome composition

EDs lead to a reduction in pathogenic bacteria and malabsorption in IBS and IBD, such as Crohn's disease. In IBD, the proportion of *Firmicutes* is decreased, whereas the fraction of Proteobacteria and Actinobacteria is increased. Enteral nutrition has low residue and contains important prebiotic properties that modify the gut microflora. Thus, it is plausible that EDs affect gut microbiota composition by changing fecal metabolic activity. Various studies also indicate that enteral nutrition reduces intestinal permeability via modulation of tight junctions and down-regulates the production of inflammatory cytokines by modulating the intestinal microbiome. EDs target gut microbiota as well as inflammation; in addition to suppressing NF- $\kappa$ B levels (a critical regulator of inflammation), they significantly lower the population of *Bacteroides fragilis*, a species linked to IBD and colorectal cancer.

One study of patients with CD revealed that the success of elemental diets in children with active small bowel/colonic CD was associated with an anti-inflammatory short chain fatty acid pattern, further suggesting the importance of ED-dependent microbiome changes. Furthermore, a clinical trial of patients given the ED for 2 weeks showed that the lactulose breath test (LBT) was normalized in the majority of IBS patients who initially showed an abnormal breath test. This indicates that the ED can drastically improve enteric flora composition and confirms its efficacy in a clinical setting. Another clinical trial of patients with CD supports this by showing a normalization of their lactulose/L-rhamnose permeability ratios coinciding with improvement in their clinical symptoms.<sup>10,24,27-30</sup>

### 7. Decreases intestinal permeability

Susceptibility to CD and IBD has been linked to genetic polymorphisms, leading to Paneth cell dysfunction or defective autophagy. This results in bacteria in the gut that would normally be non-pathogenic being allowed to adhere, translocate, and penetrate the epithelial barrier that has already been partially broken down as a result of an inflammatory diet. Persistent exposure to these bacteria then trigger an adaptive immune response, which gives way to inflammation and further breakdown of the epithelium and then more migration and sensitization to these bacterial species. A vicious bacterial penetration cycle therefore results.

An ED is thought to decrease the exposure to offending dietary components and subsequently decrease the penetration of harmful bacteria. An ED may also remove certain dietary agents (usually processed/industrialized foods), affecting microbial composition and decreasing inflammation as well as promoting the restitution of the epithelial barrier. Both of these suspected mechanisms of action lead to breaking the disease-forming, bacterial penetration cycle. As a result, intestinal permeability and inflammation from the microbiome are considerably reduced.<sup>24-26,31</sup>

### 8. Decreases inflammatory response

It is well known that cytokines are key to the regulation of the intestinal immune system and therefore mucosal inflammation. It has been shown that pro-inflammatory cytokines such as interleukin (IL)-1 $\beta$ , IL-6, IL-8, tumor necrosis factor (TNF)- $\alpha$ , and anti-inflammatory mediators like IL-1 receptor antagonist (IL-1ra) are increased in IBD. The ED plays a role in decreasing the antigen load and therefore effecting a decrease in intestinal inflammation. However, recent studies have suggested that there may also be an effect on the actual production of mucosal pro-inflammatory and anti-inflammatory cytokines. Studies have shown that patients with existing IBD, when placed on an ED for 2–4 weeks exclusively, had increased levels of vascular endothelial growth factor and transforming growth factor-beta 1 (TGF- $\beta$ 1). In addition, the levels of IL-1 $\beta$ , IL-8, IL-1ra, IL-6, TNF- $\alpha$ , and interferon- $\gamma$  were reduced.


These studies also showed that the ED reduced production of mucosal cytokines and apparently corrected an imbalance between pro-inflammatory and anti-inflammatory cytokines in these patients. Simultaneous endoscopic and histologic healing of mucosal inflammation was associated with a decline in mucosal inflammatory cytokines. Subsequently, the ED appears to exert remarkably strong immune system attenuating effects.<sup>24–26</sup>

### 9. Stimulates the migrating motor complex (MMC), a key in moving bacteria out of the small intestine and into the colon between meals

One of the most common underlying causes of SIBO is the impairment of the MMC. The MMC corresponds to cleansing waves activated approximately every 45–180 minutes in the small intestine to prevent the accumulation of debris and excessive amounts of bacteria. Pimentel and colleagues found that the MMC is decreased by 70% in SIBO patients. Apart from snacking, stress also negatively impacts the MMC. By implementing the ED, the MMC can be restored to 50% of its capacity. This is because the ED is absorbed in the first 2 ft of the small bowel, meaning it leaves the rest with no food. The ED literally starves out 80% of the bacteria in the small intestine, significantly reducing the bacterial load.<sup>10,25,26</sup>

### 10. Restores mesenteric adipose tissue

Mesenteric adipose tissue (MAT) plays an important role in the pathogenesis of CD. It is well known that mesenteric fat hypertrophy, fat wrapping or creeping fat, in patients with CD is highly typical. A study by Feng and colleagues evaluated the effects of EN on CD patients, with a focus on MAT alterations, such as adipocyte size and adipokine production. They showed that EDs ameliorate mesenteric fat alteration in IBD, apparently by restoring adipocyte morphology and diminishing the inflammatory environment of the mesenteric fat.<sup>32</sup>



Note that the complexes move down the gastrointestinal tract at a regular rate during fasting, that they are completely inhibited by a meal, and that they resume 90–120 minutes after the meal.

A plethora of simultaneous mechanisms of actions may be occurring as a result of the ED. The nutritional status of patients is not only improved, there is also an improvement in the epithelial barrier, a reduction of antigenic load, and a counteraction of dysbiosis, while intestinal immunity and adipose compartment are also directly affected. Although so far studies have been relatively promising, more need to be conducted to confirm these proposed mechanisms.

### Research summary

Numerous studies have validated the effectiveness of an ED in improving the symptoms of not only Crohn's disease,<sup>2,3</sup> but also a number of other conditions such as IBS<sup>10</sup> and SIBO.<sup>8–10</sup>

Moreover, studies have shown that EDs can improve immunoglobulin levels,<sup>26</sup> eradicate pathogenic gut bacteria better than antimicrobials,<sup>24</sup> be as effective as corticosteroids in acute CD,<sup>3</sup> and even have an effect on rheumatoid arthritis.<sup>20</sup>

In 2004, researchers published a retrospective study on 93 patients demonstrating that an ED had 80% efficacy in treating the symptoms of SIBO and IBS. Researchers found that patients not only had improved symptoms, but also normalized LBT.<sup>10</sup>

Appendix I provides a summary of some significant clinical trials that show the efficacy of the ED against the various conditions mentioned above.



## ElementAll™ Biological Diet

Pink Lemonade

Code 9234

Size/Form 1322 g Powder

### Product Overview

- Provides a hypoallergenic formula, with 100% of protein supplied from free amino acids, particularly L-glutamine, a key fuel for intestinal cells
- Contains easily assimilated and tolerated carbohydrates
- Meets all nutrient requirements, while needing little-to-no digestive functionality for macronutrient breakdown
- Excellent taste for improved compliance; available in Chocolate and Pink Lemonade flavors

### Ingredients

## Supplement Facts

Serving Size 4 Scoops (146.8 g)  
Servings Per Container 9

Amount Per Serving	% Daily Value	Amount Per Serving	% Daily Value
Calories	600	Magnesium (Citrate, Glycerophosphate)	132 mg 31%
Total Fat	13 g 17% <sup>‡</sup>	Zinc (Sulfate, Monohydrate)	8.3 mg 75%
Saturated Fat	1.5 g 8% <sup>‡</sup>	Selenium (Selenomethionine)	88 mcg 160%
Monounsaturated Fat	10 g **	Copper (Sulfate)	0.668 mg 74%
Polyunsaturated Fat	3 g **	Manganese (Citrate)	1.32 mg 57%
Total Carbohydrate	90 g 33% <sup>‡</sup>	Chromium (Picolinate)	68 mcg 194%
Dietary Fiber	4 g 14% <sup>‡</sup>	Molybdenum (Sodium Molybdate)	24 mcg 53%
Total Sugars	46 g	Sodium (Citrate, Dihydrate)	320 mg 14%
Includes 46 g Added Sugars	92% <sup>‡</sup>	Potassium (Citrate)	580 mg 12%
Protein <sup>◇</sup>		L-Glutamine	8,889 mg **
Vitamin A (Retinyl Palmitate)	1,008 mcg 112%	L-Leucine <sup>†</sup>	6,667 mg **
Vitamin C (Sodium Ascorbate)	80 mg 89%	L-Arginine	4,444 mg **
Vitamin D3 (Cholecalciferol)	5.6 mcg 28%	L-Isoleucine <sup>†</sup>	1,800 mg **
Vitamin E (d-Alpha Tocopheryl Acetate)	18.4 mg 123%	L-Valine <sup>†</sup>	1,800 mg **
Vitamin K2 (Menaquinone MK-7)	40 mcg 33%	L-Lysine	1,444 mg **
Thiamin (Hydrochloride)	2 mg 167%	L-Phenylalanine	800 mg **
Riboflavin (Riboflavin-5-Phosphate)	2 mg 154%	L-Threonine	800 mg **
Niacin (Nicotinate Acid, Tryptophan)	16 mg 100%	L-Histidine	600 mg **
Vitamin B6 (Pyridoxal-5-Phosphate)	2.6 mg 153%	L-Cysteine	556 mg **
Folate (from (6S)-5-Methyltetrahydrofolic Acid (MTHF), Glucosamine Salt, Quatrefolic <sup>®</sup> , Folic Acid)	456 mcg DFE 114%	L-Methionine	480 mg **
(268 mcg Folic Acid)		L-Tyrosine	450 mg **
B12 (Methylcobalamin)	287.4 mcg 11,975%	L-Aspartic Acid	444 mg **
Biotin	200 mcg 667%	L-Proline	444 mg **
Pantothenic Acid (Calcium d-Pantothenate)	13 mg 260%	L-Tryptophan	180 mg **
Choline (Citrate)	132 mg 24%	L-Serine	111 mg **
Calcium (Phosphate, Glycerophosphate)	680 mg 52%	L-Alanine	111 mg **
Iron (Ferrous Fumarate)	8 mg 44%	Glycine	111 mg **
Phosphorus (Calcium Phosphate, Calcium Glycerophosphate)	280 mg 22%	Taurine	44 mg **
Iodine (Potassium Iodide)	68 mcg 45%	L-Carnitine (Tartrate)	44 mg **
		Boron (Sodium Borate)	1 mg **

<sup>‡</sup> Percent Daily Values are based on a 2,000 calorie diet.

\*\* Daily Value not established.


◇ Contains 30.2 g free form amino acids per 146.8 g serving.

Other ingredients: Organic tapioca dextrose, organic tapioca maltodextrin, organic safflower oil, medium chain triglycerides (refined coconut), sunflower lecithin, natural flavor (lemon), silica, citric acid.

**Suggested Usage:** Mix one serving (4 scoops) in 500 ml of water or as directed by a health care professional. You can adjust by adding more water if desired. Take 3 servings per day or as directed by your health care professional. 3 servings (12 scoops) provide 1,800 calories.

FOR PROFESSIONAL USE ONLY. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. \*All figures and tables used with the permission of the rights holder. © All Rights Reserved Bioclinic Naturals™ 2020. June 2020. 9224220

Head office Assured Natural Distribution Inc., 104 - 3686 Bonneville Place, Burnaby, BC, Canada V3N 4T6 | U.S. Distribution office 14224 167<sup>th</sup> Avenue SE, Monroe, WA, USA 98272  
Customer service 1-877-433-9860 · Fax 1-877-433-9862 · Email customersupport@bioclinicnaturals.com · www.bioclinicnaturals.com



## ElementAll™ Biological Diet

### Chocolate

**Code** 9236

**Size/Form** 1404 g Powder

#### Product Overview

- Provides a hypoallergenic formula, with 100% of protein supplied from free amino acids, particularly L-glutamine, a key fuel for intestinal cells
- Contains easily assimilated and tolerated carbohydrates
- Meets all nutrient requirements, while needing little-to-no digestive functionality for macronutrient breakdown
- Excellent taste for improved compliance; available in Chocolate and Pink Lemonade flavors

#### Ingredients

## Supplement Facts

Serving Size 4 Scoops (156 g)  
Servings Per Container 9

	Amount Per Serving	% Daily Value		Amount Per Serving	% Daily Value
Calories	630		Magnesium		
Total Fat	13 g	17% <sup>‡</sup>	(Citrate, Glycerophosphate)	132 mg	31%
Saturated Fat	2 g	9% <sup>‡</sup>	Zinc (Sulfate, Monohydrate)	8.3 mg	75%
Monounsaturated Fat	9 g	**	Selenium (Selenomethionine)	88 mcg	160%
Polyunsaturated Fat	2 g	**	Copper (Sulfate)	0.668 mg	74%
Total Carbohydrate	93 g	34% <sup>‡</sup>	Manganese (Citrate)	1.32 mg	57%
Dietary Fiber	5 g	18% <sup>‡</sup>	Chromium (Picolinate)	68 mcg	194%
Total Sugars	46 g		Molybdenum (Sodium Molybdate)	32 mcg	71%
Includes 46 g Added Sugars		92% <sup>‡</sup>	Sodium (Citrate, Dihydrate)	380 mg	17%
Protein <sup>‡</sup>			Potassium (Citrate)	1,080 mg	23%
Vitamin A (Retinyl Palmitate)	1,008 mcg	112%	L-Glutamine	8,889 mg	**
Vitamin C (Sodium Ascorbate)	80 mg	89%	L-Leucine <sup>†</sup>	6,667 mg	**
Vitamin D3 (Cholecalciferol)	5.6 mcg	28%	L-Arginine	4,444 mg	**
Vitamin E			L-Isoleucine <sup>†</sup>	1,800 mg	**
(d-Alpha Tocopheryl Acetate)	18.4 mg	123%	L-Valine <sup>†</sup>	1,800 mg	**
Vitamin K2 (Menaquinone MK-7)	40 mcg	33%	L-Lysine	1,444 mg	**
Thiamin (Hydrochloride)	2 mg	167%	L-Phenylalanine	800 mg	**
Riboflavin (Riboflavin-5-Phosphate)	2 mg	154%	L-Threonine	800 mg	**
Niacin (Nicotinate Acid, Tryptophan)	16 mg	100%	L-Histidine	600 mg	**
Vitamin B6 (Pyridoxal-5-Phosphate)	2.6 mg	153%	L-Cysteine	556 mg	**
Folate			L-Methionine	480 mg	**
(from (6S)-5-Methyltetrahydrofolic			L-Tyrosine	450 mg	**
Acid (MTHF), Glucosamine Salt,			L-Aspartic Acid	444 mg	**
Quatrefolic®, Folic Acid)	456 mcg DFE	114%	L-Proline	444 mg	**
(268 mcg Folic Acid)			L-Tryptophan	180 mg	**
B12 (Methylcobalamin)	287.4 mcg	11,975%	L-Serine	111 mg	**
Biotin	200 mcg	667%	L-Alanine	111 mg	**
Pantothenic Acid			Glycine	111 mg	**
(Calcium d-Pantothenate)	13 mg	260%	Taurine	44 mg	**
Choline (Citrate)	132 mg	24%	L-Carnitine (Tartrate)	44 mg	**
Calcium			Boron (Sodium Borate)	1 mg	**
(Phosphate, Glycerophosphate)	688 mg	53%			
Iron (Ferrous Fumarate)	11 mg	61%			
Phosphorus (Calcium Phosphate,					
Calcium Glycerophosphate)	280 mg	22%			
Iodine (Potassium Iodide)	68 mcg	45%			

‡ Percent Daily Values are based on a 2,000 calorie diet.

\*\* Daily Value not established.

‡ Contains 30.2 g free form amino acids per 156 g serving.

Other ingredients: Organic tapioca dextrose, organic tapioca maltodextrin, organic safflower oil, medium chain triglycerides (refined coconut), natural flavor (chocolate powder, organic cocoa powder, vanilla), sunflower lecithin, silica.

**Suggested Usage:** Mix one serving (4 scoops) in 500 ml of water or as directed by a health care professional. You can adjust by adding more water if desired. Take 3 servings per day or as directed by your health care professional. 3 servings (12 scoops) provide 1,890 calories.

FOR PROFESSIONAL USE ONLY. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. \*All figures and tables used with the permission of the rights holder. © All Rights Reserved Bioclinic Naturals™ 2020. June 2020. 9224220

Head office Assured Natural Distribution Inc., 104 – 3686 Bonneville Place, Burnaby, BC, Canada V3N 4T6 | U.S. Distribution office 14224 167<sup>th</sup> Avenue SE, Monroe, WA, USA 98272  
Customer service 1-877-433-9860 · Fax 1-877-433-9862 · Email customersupport@bioclinicnaturals.com · www.bioclinicnaturals.com



## APPENDIX 1

FIRST AUTHOR, YEAR	METHODS	RESULTS
<b>CONDITION: CROHN'S DISEASE</b>		
Heuschkel, R.B., 2000 <sup>3</sup>	Randomized clinical trials comparing exclusive enteral nutrition with corticosteroids were identified. Two independent reviewers extracted data from selected studies. Studies were assessed for heterogeneity, and relative risks for remission induction with enteral nutrition were obtained. Sensitivity analyses were performed in partially randomized studies. Estimates were made of the number of studies needed to overturn the current result. Other outcome measures were qualitatively assessed.	In 5 randomized clinical trials comprising 147 patients, enteral nutrition was as effective as corticosteroids at inducing a remission (RR = 0.95 [95% confidence interval 0.67, 1.34]).
O'Morain, C., 1984 <sup>33</sup>	A controlled trial was conducted in which 21 patients acutely ill with exacerbations of CD were randomized to receive either 0.75 mg/kg/day of prednisolone or an ED (Vivonex) for 4 weeks.	Assessment at 4 and 12 weeks showed that patients treated with the ED had improved as much as, and by some criteria more than, the steroid-treated group. <b>CONCLUSION:</b> The ED is a safe and effective treatment for acute CD.
Tagaki, S., 2009 <sup>34</sup>	Fifty-one CD patients in remission were randomly assigned to a half-ED group (n=26) or a free diet group (n=25). The primary outcome measure was the occurrence of relapse during a two-year period. This study investigated the QOL of the patients and medical costs of a half-ED as secondary outcomes. QOL was evaluated using the Japanese version of the IBDQ scoring system, and monthly medical costs were calculated from receipts.	Patients on the half-ED diet had a relapse rate of 34.6%, while those on the free diet had a rate of 64%. After multi-variate adjustment, those in the half-ED group had a 60% lower risk for relapse. IBDQ score was not significantly different between the two groups at 1 and 13 months after the start of maintenance treatment. Medical costs were also not significantly different between them. <b>CONCLUSION:</b> This study confirms that the half-ED therapy reduces the risk of relapse for patients with CD, without impairing quality of life or increasing medical costs.
Sanderson, I.R., 1987 <sup>28</sup>	Fourteen children aged 11–17 years with active small bowel CD were given an ED for 6 weeks.	Investigations with iso-osmolar oral test solutions before and after this treatment showed that all 14 children had abnormally raised lactulose/L-rhamnose permeability ratios, which fell significantly after the ED. This change coincided with marked clinical improvement, as assessed by a disease activity index score.
Feng, Y., 2014 <sup>32</sup>	Sixteen patients who underwent resection for ileum CD were studied. As a control group, 8 patients without IBD were enrolled. Before operation, 8 CD patients received exclusive enteral nutrition for 4 weeks, and the other patients had no nutritional therapy. The mesenteric fat samples were obtained during operation. Adipocyte size, adipokine production, and topical C-reactive protein level were assessed.	The adipocyte size from patients treated with exclusive enteral nutrition was much larger than that from CD patients without nutritional therapy. Furthermore, protein levels of pro-inflammatory adipokines such as TNF-alpha and leptin were lower, while protein levels of adiponectin were higher in these patients. In terms of mRNA level, the expression of adiponectin was up-regulated and leptin was down-regulated in the patients who received enteral nutrition. <b>CONCLUSION:</b> Exclusive enteral nutrition could ameliorate mesenteric fat alterations, which are associated with intestinal injury in patients with CD by restoring adipocyte morphology and diminishing the inflammatory environment of mesenteric fat.
Okada, M., 1990 <sup>35</sup>	A controlled trial was conducted on 20 patients with acute CD who had never received specific treatment. The first 10 patients were put on the EDs and the remaining 10 were prescribed prednisolone for 6 weeks at an initial dose of 0.7 mg/kg/day. Patients were assessed using the simple activity index, body weight, erythrocyte sedimentation rate, C-reactive protein and alpha 2 globulin, serum albumin, and radiographic findings of bowel lesions.	At 6 weeks, the patients on the EDs showed a significantly greater improvement in the activity index, inflammatory signs such as C-reactive protein and alpha 2 globulin, and radiographic findings of bowel lesions than did those on the steroid. Patients who were given steroids for 6 weeks and then treated with the EDs for 4 weeks showed improvement in the radiographic findings of bowel lesions and inflammation. <b>CONCLUSION:</b> The study strongly suggests that EDs are superior to steroids for treating active CD.

APPENDIX 1 *continued*

FIRST AUTHOR, YEAR	METHODS	RESULTS
<b>CONDITION: IBS AND SIBO</b>		
Pimental, M., 2004 <sup>10</sup>	This study evaluated the ability of an ED to normalize the LBT in IBS subjects with abnormal breath test findings. Consecutive subjects with IBS and abnormal LBT suggesting the presence of bacterial overgrowth underwent a two-week exclusive ED. The diet consisted of Vivonex Plus in a quantity based on individual caloric requirement. On day 15 (prior to solid food), subjects returned for a follow-up breath test and those with an abnormal LBT were continued on the diet for an additional 7 days. The ability of an ED to normalize the LBT was determined for days 15 and 21. A chart review was then conducted to evaluate any clinical benefit one month later.	Of the 93 subjects available for analysis, 74 (80%) had a normal LBT on day 15 of the ED. When those who continued to day 21 were included, 5 additional patients normalized the breath test (85%). On chart review, subjects who successfully normalized their breath test had a 66.4 +/-36.1% improvement in bowel symptoms, compared to 11.9 +/-22.0% in those who failed to normalize ( $P < 0.001$ ).  <b>CONCLUSION:</b> An ED is highly effective in normalizing an abnormal LBT in IBS subjects, with a concomitant improvement in clinical symptoms.
<b>CONDITION: RHEUMATOID ARTHRITIS</b>		
Haugen, M.A., 1994 <sup>36</sup>	To evaluate the extent of food allergy/intolerance in rheumatoid arthritis, an elemental (hypoallergenic) diet was studied in a controlled, double-blind pilot study. Ten patients were allocated to an experimental group and 7 to a control group. The patients in the experimental group received an ED for 3 weeks, whereas the patients in the control group received a control soup consisting of milk, meat, fish, shellfish, orange, pineapples, tomatoes, peas, and flour from wheat and corn. During the 4 <sup>th</sup> week of the study, the patients in both groups resumed their regular diet.	A significant improvement was found in the number of tender joints ( $p = 0.04$ ) in the experimental group, whereas improvement was found in the erythrocyte sedimentation rate (ESR) ( $p = 0.03$ ) and in the thrombocyte count ( $p = 0.02$ ) in the control group. Three patients in the ED group and 2 patients in the control group improved in all of the measured disease variables during the dietary treatment period. There was no significant difference in disease activity variables between the two groups. These results suggest that some RA patients may respond to the elimination of offending food items. However, the results do not encourage treatment with an ED in unselected RA patients.
<b>CONDITION: ECZEMA</b>		
Devlin, J., 1991 <sup>21</sup>	A total of 37 children with refractory wide-spread atopic eczema were treated with an antigen avoidance regimen comprising hospitalization, exclusive feeding with an elemental formula for a median duration of 30 days, and measures to reduce exposure to pet and dust mite antigens at home. After the initial period of food exclusion, food challenges were performed at intervals of 7 days, and the patients followed up for at least 12 months.	Improvement in the eczema was seen in 27 of the 37 (73%) patients. By discharge from hospital, their disease severity score had fallen to a median of 27% of the pretreatment figure, and only 3 of the 27 required topical corticosteroids.
<b>CONDITION: DERMATITIS HERPETIFORMIS</b>		
Kadunce, D.P., 1991 <sup>22</sup>	At entry, 8 patients with dermatitis herpetiformis who were consuming unrestricted diets were stabilized on their suppressive medications at dosage levels that allowed individual lesions to erupt. Six patients were then given an ED plus 30 g of gluten daily for 2 weeks, followed by the ED alone for 2 weeks. Conversely, 2 patients received an ED alone for 2 weeks followed by an ED plus gluten during the final 2 weeks. Small bowel biopsies, skin biopsies, and clinical assessments were done at 0, 2, and 4 weeks.	Suppressive medication dose requirement decreased over the 4 weeks by a mean of 66%. Six of 8 subjects significantly improved clinically during the gluten-challenge phase of the ED and all were improved at the end of the study. The amount of IgA in perilesional skin did not change significantly, but the amount of C3 increased in 5 of 7 evaluable subjects after gluten challenge. Circulating anti-gluten and anti-endomysial antibodies were not significantly affected by the diets. All subjects completing evaluable small bowel biopsies (7) demonstrated worsening of their villus architecture (by scanning electron microscopy and intraepithelial lymphocyte counts) during gluten challenge and improvement (6 subjects) after 2 weeks of elemental dietary intake.  <b>CONCLUSION:</b> Researchers concluded that there is a significant improvement in clinical disease activity on an ED, independent of gluten administration; small bowel morphology improves rapidly on an ED; and complement deposition. However, neither IgA deposition nor circulating antibody levels correlate with gluten intake. It seems likely that dietary factors other than gluten are important in the pathogenesis of the skin lesions in dermatitis herpetiformis.

## REFERENCES

1. Russel, R.I. (1975). Elemental diets. *Gut*, 16(1), 68-79.
2. Teahon, K., Bjarnason, I., Pearson, M., et al. (1990). Ten years' experience with an elemental diet in the management of Crohn's disease. *Gut*, 31(10), 1133-1137.
3. Heuschkel, R.B., Menache, C.C., Megerian, J.T., et al. (2000). Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. *Journal of Pediatric Gastroenterology and Nutrition*, 31(1), 8-15.
4. O'Sullivan, M., & O'Morain, C. (2006). Nutrition in inflammatory bowel disease. *Best Practices & Research: Clinical Gastroenterology*, 20(3), 561-573.
5. Sitrin, M.D. (1992). Nutrition support in inflammatory bowel disease. *Nutrition in Clinical Practice*, 7(2), 53-60.
6. Voitk, A.J., Echave, V., Feller, J.H., et al. (1973). Experience with elemental diet in the treatment of inflammatory bowel disease. Is this primary therapy? *Archives of Surgery*, 107(2), 329-333.
7. Richman, E., & Rhodes, J.M. (2013). Review article: evidence-based dietary advice for patients with inflammatory bowel disease. *Alimentary Pharmacology & Therapeutics*, 38, 1156-1171.
8. Rezaie, A., Pimentel, M., & Rao, S.S. (2016). How to test and treat small intestinal bacterial overgrowth: an evidence-based approach. *Current Gastroenterology Reports*, 18(2), 8.
9. Chedid, V., Dhalla, S., Clarke, J.O., et al. (2014). Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. *Global Advances in Health and Medicine*, 3(3), 16-24.
10. Pimentel, M., Constantino, T., Kong, Y., et al. (2004). A 14-day elemental diet is highly effective in normalizing the lactulose breath test. *Digestive Diseases and Sciences*, 49(1), 73-77.
11. Hopman, W.P., de Jong, A.J., Rosenbusch, G., et al. (1987). Elemental diet stimulates gallbladder contraction and secretion of cholecystokinin and pancreatic polypeptide in man. *Digestive Diseases and Sciences*, 32(1), 45-49.
12. Winitz, M., Adams, R.F., Seedman, D.A., et al. (1970). Studies in metabolic nutrition employing chemically defined diets. *American Journal of Clinical Nutrition*, 23(5), 546-549.
13. Bury, K.D., Stephens, R.V., & Randall, H.T. (1971). Use of a chemically defined, liquid, elemental diet for nutritional management of fistulas of the alimentary tract. *American Journal of Surgery*, 121(2), 174-183.
14. Bounous, G. (1989). Elemental diets in the prophylaxis and therapy for intestinal lesions: an update. *Surgery*, 105(5), 571-575.
15. Voitk, A., Brown, R.A., Echave, V., et al. (1973). Use of an elemental diet in the treatment of complicated pancreatitis. *American Journal of Surgery*, 125(2), 223-227.
16. Ikeura, T., Takaoka, M., Uchida, K., et al. (2014). Beneficial effect of low-fat elemental diet therapy on pain in chronic pancreatitis. *International Journal of Chronic Diseases*, 2014, 862091.
17. Mukau, L., Talamini, M.A., & Sitzmann, J.V. Elemental diets may accelerate recovery from total parenteral nutrition-induced gut atrophy. *The Journal of Parenteral and Enteral Nutrition*, 18(1), 75-78.
18. Johnston, B.T., & McFarland, R.J. (1995). Elemental diet in the treatment of pneumatosis coli. *Scandinavian Journal of Gastroenterology*, 30(12), 1224-1227.
19. Olaussen, R.W., Løvik, A., Tollefsen, S., et al. (2005). Effect of elemental diet on mucosal immunopathology and clinical symptoms in type 1 refractory celiac disease. *Clinical Gastroenterology and Hepatology*, 3(9), 875-885.
20. Darlington, L.G. (1994). Dietary therapy for rheumatoid arthritis. *Clinical and Experimental Rheumatology*, 12(3), 235-239.
21. Devlin, J., David, T.J., & Stanton, R.H. (1991). Elemental diet for refractory atopic eczema. *Archives of Disease in Childhood*, 66(1), 93-99.
22. Kadunce, D.P., McMurry, M.P., Avots-Avotins, A., et al. (1991). The effect of an elemental diet with and without gluten on disease activity in dermatitis herpetiformis. *Journal of Investigative Dermatology*, 97(2), 175-182.
23. Merriam-Webster. (n.d.). Definition of "elemental." Retrieved from <https://www.merriam-webster.com/dictionary/elemental>.
24. Tan, X., Mao, J., Tang, H., et al. (2017). Mechanisms underlying clinical efficacy of enteral nutrition in inflammatory bowel disease. *International Journal of Clinical and Experimental Medicine*, 10(2), 2026-2035.
25. Wędrychowicz, A., Zajac, A., & Tomasik, P. (2016). Advances in nutritional therapy in inflammatory bowel diseases. *World Journal of Gastroenterology*, 22(3), 1045-1066.
26. Triantafyllidis, J.K., Vagianos, C., & Papalois, A.E. (2015). The role of enteral nutrition in patients with inflammatory bowel disease: current aspects. *Biomed Research International*, 2015, 197167.
27. Kajuru, T., Takeda, T., Sakata, S., et al. (2009). Change of intestinal microbiota with elemental diet and its impact on therapeutic effects in a murine model of chronic colitis. *Digestive Diseases and Sciences*, 54(9), 1892-1900.
28. Sanderson, I.R., Boulton, P., Menzies, I., et al. (1987). Improvement of abnormal lactulose/rhamnose permeability in active Crohn's disease of the small bowel by an elemental diet. *Gut*, 28(9), 1073-1076.
29. Shiga, H., Kajuru, T., Shinozaki, J., et al. (2012). Changes of faecal microbiota in patients with Crohn's disease treated with an elemental diet and total parenteral nutrition. *Digestive and Liver Disease*, 44(9), 736-742.
30. Zamani, S., Hesam Shariati, S., et al. (2017). Detection of enterotoxigenic *Bacteroides fragilis* in patients with ulcerative colitis. *Gut Pathogens*, 9, 53.
31. Levine, A., & Wine, E. (2013). Effects of enteral nutrition on Crohn's disease: clues to the impact of diet on disease pathogenesis. *Inflammatory Bowel Disease*, 19, 1322-1329.
32. Feng, Y., Li, Y., Mei, S., et al. (2014). Exclusive enteral nutrition ameliorates mesenteric adipose tissue alterations in patients with active Crohn's disease. *Clinical Nutrition*, 33, 850-858.
33. O'Morain, C., Segal, A.W., & Levi, A.J. (1984). Elemental diet as primary treatment of acute Crohn's disease: a controlled trial. *British Medical Journal (Clinical Research Education)*, 288(6434), 1859-1862.
34. Takagi, S., Utsunomiya, K., Kuriyama, S. et al. (2009). Quality of life of patients and medical cost of "half elemental diet" as maintenance therapy for Crohn's disease: secondary outcomes of a randomised controlled trial. *Digestive and Liver Disease*, 41(6), 390-394.
35. Okada, M., Yao, T., Yamamoto, T., et al. (1990). Controlled trial comparing an elemental diet with prednisolone in the treatment of active Crohn's disease. *Hepatology*, 37(1), 72-80.
36. Haugen, M.A., Kjeldsen-Kragh, J., Førre, O. (1994). A pilot study of the effect of an elemental diet in the management of rheumatoid arthritis. *Clinical and Experimental Rheumatology*, 12(3), 275-279.



# Elemental Diet Protocol

## **Assessment**

Depending on the patient's condition, various means of assessment may be applied. For example, clinical trials for participants with Crohn's disease typically monitor the frequency of remission, though one trial assessed small bowel permeability with sugar markers of permeability. All children enrolled in this trial had an elevated lactulose/rhamnose ratio before beginning dietary therapy, and by six weeks of an ED all had significant improvement, with 50% achieving normal values.<sup>1</sup> For individuals with increased intestinal permeability, sugar ratios may be one simple method of monitoring progress.

For individuals with suspected SIBO, a common non-invasive test is the lactulose breath test (LBT). Among participants with IBS and SIBO, after two weeks of an ED, 80% had normal LBTs, while 85% achieved normal results after an additional week of dietary therapy. Normalization of LBTs also correlated closely with clinical improvement in bowel symptoms.<sup>2</sup>

For those with rheumatoid arthritis, standard clinical measures can be used for assessment, such as early morning stiffness, pain on a visual analog scale, etc.<sup>3</sup>

## **General Recommendations**

With any dietary supplement or medical food, administration and dosing are important components in achieving desired outcomes, and EDs are no different. Understanding these protocols can help the health care professional achieve the treatment objectives. An important factor in the administration and selection of an ED protocol is the health care professional's assessment and purpose for using it. These considerations will be important in calculating the proper protocol for each patient.

The most clinically studied of the EDs is the full elemental diet (full ED), with most clinical trials employing 100% of calories from an ED for a two-week period, though some have extended it for 4–6 weeks. This type of ED was first used in patients with limited or impaired capacity to digest, absorb, and/or metabolize foods. As mentioned earlier, an exclusive ED is implemented in inflammatory bowel disease (IBD) and those conditions that go hand in hand with IBD, such as SIBO and even IBS. Continued research into the microbiome and the relationship between gut health and systemic health, including the brain-gut connection, has also led to the development and use of shorter EDs, which may help jump-start gut healing.

In addition to use as a short-term therapy, a half elemental diet (half ED) may extend the benefits achieved with a full ED. In clinical practice, once the ED has produced the required effects, a half ED can be implemented. In this type of diet, half of the human physiological caloric requirements are met with the ED formula and the other half through whole, hypoallergenic foods. Clinical studies have shown that patients have better overall long-term effects when they employ a half ED immediately following a full ED in the management of conditions such as CD.<sup>4,5</sup>

## Protocols

### Part A: Calculating nutritional requirements

1. First calculate the patient's basal metabolic rate (BMR):
  - a. Women:  $BMR = 655 + (4.35 \times \text{weight in pounds}) + (4.7 \times \text{height in inches}) - (4.7 \times \text{age in years})$
  - c. Men:  $BMR = 66 + (6.23 \times \text{weight in pounds}) + (12.7 \times \text{height in inches}) - (6.8 \times \text{age in years})$
2. Final calculation with the Harris-Benedict Equation. This formula uses the calculated BMR and then applies an activity factor to determine the patient's actual total daily energy expenditure in calories. The more active a person is, the more calories they will use. Harris-Benedict Factors are the following:
  - a. Little-to-no exercise:  $BMR \times 1.2 = \text{total daily calories}$
  - b. Light exercise/sports 1–3 days/week:  $BMR \times 1.375 = \text{total daily calories}$
  - c. Moderate (moderate exercise/sports 3–5 days/week):  $BMR \times 1.55 = \text{total daily calories}$
  - d. Very active (hard exercise/sports 6–7 days/week):  $BMR \times 1.725 = \text{total daily calories}$
  - e. Extra active (very hard exercise/sports 6–7 days/week):  $BMR \times 1.9 = \text{total daily calories}$ .<sup>6–8</sup>

### PART B: Different forms of the ED

#### 1. Full ED

The patient consumes 100% of caloric requirements using the ED. This becomes the patient's sole source of nutrition for the designated time period, which normally spans 14 days (as evidenced by clinical trials).<sup>9–19</sup>

**Application:** CD, SIBO, and IBS.<sup>11,18</sup>

**Dosage:** To accurately calculate the patient's total caloric needs, determine their BMR and then use the Harris-Benedict equation above to calculate total caloric requirements (approximately 1,800 calories per day). Advise the patient to take the calories in divided doses during the day: approximately 200–300 calorie servings every 2–3 hours over a 30-minute period until the caloric requirements are met.

**Duration:** Two weeks has been clinically validated. This time period can be extended at the sole discretion of the health care professional, if necessary.

#### 2. Half ED

The patient consumes 50% of their daily caloric needs from the ED and the other 50% from a whole food diet. The scientific literature has found that half EDs (sometimes called partial EDs) help with maintaining remission of CD.<sup>20</sup> They can also be used when compliance becomes difficult for patients on full EDs for SIBO and IBS. In addition, half EDs can be used as starting and exiting conduits to full EDs, easing the patient's experience and possibly improving compliance.<sup>5</sup>

**Application:** Maintaining remission of CD after completion of the full ED, used as conduits to full EDs and in place of full EDs for patients having difficulty with compliance. This will be at the discretion of the health care professional.<sup>5</sup>

**Dosage:** The dose supplied by the half ED is 50% of the daily total calories divided into 200–300 calorie servings, consumed every 2 hours (use either first or second half of day). Whatever part of the day where the half ED is not used, the patient consumes a whole food diet.

To accurately calculate the patient's total needs, determine their BMR and then use the Harris-Benedict equation (see above) to calculate total caloric requirement (divide this by half to give the calories needed from the half ED, which should be approximately 900 calories per day).<sup>5</sup>

**Duration:** There are no published reports specifically demonstrating the optimal duration of a half ED, however, 4–6 weeks can be a good starting point. The duration would be calculated at the discretion of the health care professional, considering patient symptomatology and other markers deemed important.

### 3. Short ED

This can be used to give the gastrointestinal tract a “rest” by avoiding all the complex processes involved in digestion, including allergen and by-product exposure created through digestive and absorption processes. This can be useful in helping support gut mucosal healing processes. Due to the short duration, compliance is usually very good and may be used as a “bridge” to introduce the full ED.

**Dosage:** In a short ED, dosing can follow either the full-ED or half-ED directives, and calculations can be made accordingly.

**Duration:** There are no published data regarding the duration of a short ED, however 1–3 days is generally the accepted time frame.

### 4. Intermittent ED

Although intermittent EDs have no clinical research, some health care professionals believe that some benefit could be gained from giving the gastrointestinal tract a period of “rest” during parts of the day. In particular, the possible restoration of the migrating motor complex and, in turn, overall gastrointestinal health may benefit from an intermittent ED acting as a type of fast without compromising nutritional status.

**Dosage:** Intermittent EDs will entail consuming 300 calories over a 15-minute period.

**Duration:** There are no published studies on this type of use of the ED, but much like intermittent fasting, it can go on for several months. It is important to always be under the guidance of a health care professional during this time.

**Note:** No food or beverages should be consumed during the ED (water is unrestricted), however in specific cases there can be continued observable therapeutic effects with the addition of chicken or steak (no fat), herbal or black tea, or black coffee.

### Part C: After the ED

Upon completion of the ED, a transition diet is recommended along with prokinetics with meals to prevent bloating and help with motility.

- Prokinetics with meals:
  - Ginger: 500 mg with each meal
  - Prescription medication at night
- Transition diet:
  1. Days 1–2: No fiber, meats, eggs, lactose
  2. Days 2–3: Add cooked pureed low FODMAP/fiber vegetables (e.g., carrots, zucchini)
  3. Day 4: Back to whole foods diet

### Part D: Patient monitoring

Elemental diets are completed under the supervision of a health care professional, where several markers are monitored:

1. Compliance – Ensure that patients report the correct number of calories being consumed per day, according to directives.<sup>21</sup>
2. Weight – Monitoring weight is important as there will be some weight reduction in the first week of treatment on the full ED. Monitoring this marker also ensures that caloric consumption needs are being met during the diet.<sup>21</sup>
3. Symptoms – Monitor symptoms throughout the program, such as cramping and diarrhea due to osmolality, constipation, and nausea. The patient should report all of these symptoms as the diet may need to be adjusted as a result.<sup>21</sup>
4. Lactulose breath test (LBT) – This test helps diagnose SIBO, a condition that often goes hand in hand with IBS and IBD. Lactulose is a large sugar that is not digested by the body and thus has the ability to travel through the entire small intestine. During the test, patients are given a bolus of lactulose and then they collect breath over a period of time. Bacteria will take the lactulose and produce gases that include hydrogen and methane, depending on the type and quantity of bacteria. If certain percentages of gases are found in the breath, a diagnosis of SIBO is given.<sup>22</sup> As noted previously, the vast majority of individuals with IBS and abnormal lactulose breath tests had normal values after three weeks of following an ED diet. Repeat testing may be considered if symptoms return, particularly if the ED diet has been discontinued.

#### REFERENCES:

1. Sanderson, I.R., Boulton, P., Menzies, I., et al. (1987). Improvement of abnormal lactulose/rhamnose permeability in active Crohn's disease of the small bowel by an elemental diet. *Gut*, 28(9), 1073-1076.
2. Pimentel, M., Constantino, T., Kong, Y., et al. (2004). A 14-day elemental diet is highly effective in normalizing the lactulose breath test. *Digestive Diseases and Sciences*, 49(1), 73-77.
3. Podas, T., Nightingale, J.M., Oldham, R., et al. (2007). Is rheumatoid arthritis a disease that starts in the intestine? A pilot study comparing an elemental diet with oral prednisolone. *Postgraduate Medical Journal*, 83(976), 128-131.
4. Ueno, F., Matsui, T., Matsumoto, T., et al. (2013). Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan. *Journal of Gastroenterology*, 48(1), 31-72.
5. Takagi, S., Utsunomiya, K., Kuriyama, S., et al. (2009). Quality of life of patients and medical cost of "half elemental diet" as maintenance therapy for Crohn's disease: secondary outcomes of a randomised controlled trial. *Digestive and Liver Disease*, 41(6), 390-394.
6. Douglas, C.C., Lawrence, J.C., Bush, N.C., et al. (2007). Ability of the Harris Benedict formula to predict energy requirements differs with weight history and ethnicity. *Nutrition Research*, 27(4), 194-199.
7. Roza, A.M., & Shizgal, H.M. (1984). The Harris Benedict equation reevaluated: resting energy requirements and the body cell mass. *The American Journal of Clinical Nutrition*, 40(1), 168-182.
8. Mifflin, M.D., St Jeor, S.T., Hill, L.A., et al. (1990). A new predictive equation for resting energy expenditure in healthy individuals. *The American Journal of Clinical Nutrition*, 51(2), 241-247.
9. Russel, R.I. (1975). Elemental diets. *Gut*, 16(1), 68-79.
10. Teahon, K., Bjarnason, I., Pearson, M., et al. (1990). Ten years' experience with an elemental diet in the management of Crohn's disease. *Gut*, 31(10), 1133-1137.
11. Heuschkel, R.B., Menache, C.C., Megerian, J.T., et al. (2000). Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. *Journal of Pediatric Gastroenterology and Nutrition*, 31(1), 8-15.
12. O'Sullivan, M., & O'Morain, C. (2006). Nutrition in inflammatory bowel disease. *Best Practices & Research: Clinical Gastroenterology*, 20(3), 561-573.
13. Sitrin, M.D. (1992). Nutrition support in inflammatory bowel disease. *Nutrition in Clinical Practice*, 7(2), 53-60.
14. Voitk, A.J., Echave, V., Feller, J.H., et al. (1973). Experience with elemental diet in the treatment of inflammatory bowel disease. Is this primary therapy? *Archives of Surgery*, 107(2), 329-333.
15. Richman, E., & Rhodes, J.M. (2013). Review article: evidence-based dietary advice for patients with inflammatory bowel disease. *Alimentary Pharmacology & Therapeutics*, 38, 1156-1171.
16. Rezaie, A., Pimentel, M., & Rao, S.S. (2016). How to test and treat small intestinal bacterial overgrowth: an evidence-based approach. *Current Gastroenterology Reports*, 18(2), 8.
17. Chedid, V., Dhalla, S., Clarke, J.O., et al. (2014). Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. *Global Advances in Health and Medicine*, 3(3), 16-24.
18. Pimentel, M., Constantino, T., Kong, Y., et al. A 14-day elemental diet is highly effective in normalizing the lactulose breath test. *Digestive Diseases and Sciences*, 49(1), 73-77.
19. Hopman, W.P., de Jong, A.J., Rosenbusch, G., et al. (1987). Elemental diet stimulates gallbladder contraction and secretion of cholecystokinin and pancreatic polypeptide in man. *Digestive Diseases and Sciences*, 32(1), 45-49.
20. Levine, A., & Wine, E. (2013). Effects of enteral nutrition on crohn's disease: clues to the impact of diet on disease pathogenesis. *Inflammatory Bowel Disease*, 19, 1322-1329.
21. Koretz, R.L., & Meyer, J.H. (1980). Elemental diets — facts and fantasies. *Gastroenterology*, 78(2), 393-410.
22. Mattsson, J., Minaya, M.T., Monegra, M., et al. (2017). Outcome of breath tests in adult patients with suspected small intestinal bacterial overgrowth. *Gastroenterology and Hepatology from Bed to Bench*, 10(3), 168-172.